Emerging Growth's  Instablog

Emerging Growth
Send Message
My scope is to assist private companies both abroad and domestic wishing to go public in the U.S. We invest in the company in the earliest stages, and assist in coordinating their audit, legal RTO or IPO. We also offer M&A identification, execution and consulting, Investors relations... More
My company:
My blog:
  • Could This Biotech Firm Help Bring Back Stem Cells? 3 comments
    Aug 5, 2014 11:29 AM | about stocks: CUR

    (click to enlarge)Stem Cells have long been a controversial subject in Washington. Democrats and Republicans battle to determine whether or not the methodology of stem cells is humane and efficient for scientific use. As politicians continue to favor "political war games" over sound principles and the needs of their constituents, it is widely accepted within the scientific community that stem cells could be the next major medical breakthrough towards curing many mental and physical ailments Americans suffer from on a daily basis. With political opinions aside, people that suffer from central nervous system (NYSE:CNS) diseases face a daily battle with their ailments and certainly it must be frustrating to witness a potential cure in stem cells and watch politicians battle over formalities and nonsense. A case in point was a stem cell funding ban that was signed into law under the Bush Administration which led several top stem cell scientists to take their cutting edge projects overseas. This puts the United States behind in its efforts to maintain new, cutting edge technologies, which the American people deserve.

    The stock I will be talking about today is a biopharmaceutical firm that specializes in CNS treatments based on stem cells. The company has several treatments currently in Phase I and II trials to treat spinal cord ailments, psychological ailments and brain ailments. The stock is Neuralstem, Inc. (NYSE:CUR).

    Turning to the fundamentals, Neuralstem has a market cap of $288.91 million and is currently rated a "Buy" by analysts. The company is not yet profitable as it still has some ways to go in its drug trials before the FDA can allow the treatments to be approved. Price to sales is a whopping 24756, price to book is 10.74 and price to cash is 8.68. Earnings are expected to decline 59 percent this year, and decline 4 percent next year. Short sellers are establishing a foothold with a short float of 8.62 percent. Performance has been great: up 88.14 percent in past year and up almost 14.5 percent year-to-date.

    Despite not having earnings and still in the early to middle stages in its FDA trials, the stock has performed very well as speculators buy on the hopes of these treatments being approved and generating big earnings. While this stock is certainly very interesting to me over the long-term, I would advise investors to not get caught up in the speculation fever this stock is experiencing. The reason being is that if there is some sort of issue in the trails, the stock is going to be hit extremely hard and it is not worth taking that kind of risk until a clearer picture of how the trials are going and the FDA's comments on said trials. Savvy investors should place this name on a watch list and continue to monitor any news updates for the time being.

    Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Stocks: CUR
Back To Emerging Growth's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (3)
Track new comments
  • fierroargento
    , contributor
    Comments (45) | Send Message
    As a statistics professional the evidence shown so far is extremely compelling as they are showing clear for 189 that it is highly unlikely it does not have some type of positive effect. At the same time 566 for ALS trials are showing improvements on several patients on a disease that very rarely stops advancing. With this I do think the therapy will work however this is still not enough to conclude that the stock will be a 10 or 20 bagger but definitely worth the risk.
    For biotech the only financial metrics you look at is cash and burning speed of cash. From a trading perspective short interest and other technicals are relevant but not much else.
    5 Aug 2014, 05:04 PM Reply Like
  • JKenser
    , contributor
    Comments (577) | Send Message
    Wow, what fantastic analysis!!! Where did you get your fundamental analysis from Yahoo finance? I seriously do not understand the point of an article like this. This is all completely useless information..
    5 Aug 2014, 06:24 PM Reply Like
  • BioNoob
    , contributor
    Comments (178) | Send Message
    I'm not sure the intent of this article. $CUR really didn't have a great appreciation, if anything it has been facing headwind and currently a fantastic buy right now in the high 2s-low 3s. I think there has been some media exposure that have tauted the effect of 566, but for myself and possibly others we are cautiously optimistic and waiting for more news and data.


    I'll agree with you on one thing, I am speculating not investing in this company right now. From the data that have been release and efficacy testimonies, I think this is a company with tremendous upside potential. Let's say if April was able to walk again...this stock will have the biggest one day gain in the history of the market. http://aprilals.com This is an investing website, but I do hope that the treatment does improve her condition.


    5 Aug 2014, 07:41 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.